Catalent Expands Controlled-Release Manufacturing Facility - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Catalent Expands Controlled-Release Manufacturing Facility
Catalent invests $35 million in major expansion of its Winchester facility

Catalent is investing nearly $35 million in a major expansion of its controlled-release drug manufacturing facility in Winchester, Kentucky. Construction started on June 12, 2013, with the expansion expected to be completed by October 2014. The company’s 100,000 square-foot facility will be expanded by almost 80,000 square feet and will add as many as 90 new employees at the expanded site.

“The expanded Winchester facility will provide our customers with enhanced access to custom equipment capabilities and our market-leading controlled release solutions and technologies,” said Steve Havel, General Manager of Catalent’s Winchester facility, in a press statement.

The Winchester facility, opened in 1992, is one of the company’s main sites for advanced oral controlled-release drug formulation and manufacturing and this expansion follows several investments Catalent has made in advanced delivery technologies globally.

“As with Winchester, Catalent continues to invest to meet the most critical needs of the industry, including recently announced inhalation facility expansion in North Carolina, our recently completed biologics expansion in Wisconsin, and our two new ventures in China, which will focus on softgel technologies and clinical trial supplies.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here